glp 1 agonist exenatide Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Harnessing the Incretin System with

In patients with CKD who are at increased risk for cardiovascular events, use of a GLP-1 RA may reduce the risk of progression of albuminuria, cardiovascular events, or both

PloS One (2020) 15:e0227105

Market cap gains far exceed historical trends: In an equivalent time period prior to the launch of their GLP-1 products, the combined market cap gains for Novo Nordisk and Eli Lilly was significantly lower at $197 billion3.5x less than the gains realized after the introduction of these products

Patients with diabetes already face elevated pancreatitis risk due to obesity, hypertriglyceridemia, and metabolic syndromeconditions common among those prescribed GLP-1 medications

A spokesperson from Pfizer outlined the incident to Tides Global

Weight loss is an incredibly complex topic, which is why I recommend an integrative approach that can incorporate both conventional and holistic modalities